Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
| Descriptor ID |
D009364
|
| MeSH Number(s) |
C04.697.655 C23.550.727.655
|
| Concept/Terms |
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 6 | 9 |
| 1996 | 7 | 9 | 16 |
| 1997 | 4 | 8 | 12 |
| 1998 | 0 | 7 | 7 |
| 1999 | 6 | 4 | 10 |
| 2000 | 5 | 13 | 18 |
| 2001 | 3 | 10 | 13 |
| 2002 | 4 | 4 | 8 |
| 2003 | 9 | 9 | 18 |
| 2004 | 10 | 11 | 21 |
| 2005 | 6 | 14 | 20 |
| 2006 | 17 | 11 | 28 |
| 2007 | 13 | 14 | 27 |
| 2008 | 8 | 16 | 24 |
| 2009 | 14 | 12 | 26 |
| 2010 | 19 | 19 | 38 |
| 2011 | 14 | 7 | 21 |
| 2012 | 15 | 12 | 27 |
| 2013 | 20 | 19 | 39 |
| 2014 | 17 | 17 | 34 |
| 2015 | 21 | 16 | 37 |
| 2016 | 27 | 14 | 41 |
| 2017 | 27 | 8 | 35 |
| 2018 | 18 | 20 | 38 |
| 2019 | 30 | 23 | 53 |
| 2020 | 22 | 30 | 52 |
| 2021 | 21 | 21 | 42 |
| 2022 | 6 | 43 | 49 |
| 2023 | 1 | 39 | 40 |
| 2024 | 8 | 22 | 30 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
How to Predict Recurrence After Resection of Hepatocellular Carcinoma. Anticancer Res. 2025 Jan; 45(1):189-199.
-
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 01; 23(1).
-
Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study. J Immunother Cancer. 2024 Nov 03; 12(11).
-
Medullary Thyroid Cancer: Single Institute Experience Over 3 Decades and Risk Factors for Recurrence. J Clin Endocrinol Metab. 2024 Oct 15; 109(11):2729-2734.
-
ASO Author Reflections: Breast-Conserving Surgery After Neoadjuvant Systemic Therapy for Early-Stage Breast Cancer: Quantitative Biomarkers and Disparities in the Precision-Medicine Era. Ann Surg Oncol. 2024 Dec; 31(13):8904-8905.
-
Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database. Radiother Oncol. 2024 Dec; 201:110532.
-
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer. Ann Surg Oncol. 2024 Dec; 31(13):8829-8842.
-
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol. 2024 Dec; 42(34):4095-4102.
-
Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2024 Sep 01; 10(9):1179-1186.
-
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2024 Oct; 189:138-145.